SBIR/STTR Research Award

Development of a high-throughput assay for measuring m6A demethylase activity

Award identifier e4d329222fb7e51ebdeed65379e357ae5a3b48e37ab1af9b2e36a03dae8b9f86Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$192,702

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Base5 Biosciences Inc
Proposal award date
2015-02-01
Contract end date
2016-01-31
UEI
Not reported
Solicitation number
DA15-001
Topic code
NIDA

Research abstract

DESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism in cells Much of our understanding of the physiological importance of m A comes from studies of m A demethylases Indeed disruption of the m A demethylase FTO leads to dysfunction of dopaminergic pathways in the brain and an abnormal response to cocaine in mice Additionally FTO genetic mutations have been strongly associated with diseases including melanoma and breast cancer in humans Despite the importance of FTO for human health and disease tools which directly measure FTO activity have not been developed In this proposal we use a simple yet innovative RNA aptamer based strategy to develop assays which measure the activity of FTO and other m A demethylating enzymes The results of this Phase I SBIR will be the development of an optimized fluorescence assay for measuring m A demethylase activity and demonstration of the compatibility of this tool for high throughput screening of small molecule FTO inhibitors This application will enable us to develop the first commercially viable assay for measuring FTO activity which will fulfill an important need in the RNA methylation and FTO research communities Furthermore these experiments will enable the development of HTS assays for the identification of novel inhibitors of FTO and other RNA demethylase enzymes PUBLIC HEALTH RELEVANCE Disruption of the FTO gene has been strongly associated with a variety of human diseases and FTO was recently shown to influence dopaminergic pathways and the response to drugs of abuse Researchers recently discovered that FTO functions to demethylate the highly prevalent base modification N methyladenosine m A in mRNAs however tools for measuring FTO activity have not yet been developed The goal of this project is to develop an assay for measuring m A demethylase activity which can eventually be used in high throughput screens to identify small molecule inhibitors of FTO and other m A demethylases This tool will enable the discovery of drugs which target m A demethylating enzymes and will facilitate the development of novel therapies for human disease

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.